Randomized study of docetaxel or weekly paclitaxel followed by 5FU + epirubicin + cyclophosphamide as preoperative chemotherapy for primary breast cancer
Not Applicable
- Conditions
- primary breast cancer
- Registration Number
- JPRN-UMIN000000916
- Lead Sponsor
- kobe breast cancer oncology group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) severe comorbidity 2) alergy to polysorbate 80 3) alergy to clemohol EL 4) active infection 5) severe peripheral neuropathy 6) alcohol intolerance 7) pregnant or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pathological complete response rate
- Secondary Outcome Measures
Name Time Method clinical response rate, safety, breast conserving rate, progression free survival, overall survival